Cover Image
市場調查報告書

RedHill Biopharma Ltd.- 產品平台檢討

RedHill Biopharma Ltd. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 257865
出版日期 內容資訊 英文 49 Pages
訂單完成後即時交付
價格
Back to Top
RedHill Biopharma Ltd.- 產品平台檢討 RedHill Biopharma Ltd. - Product Pipeline Review - 2015
出版日期: 2015年05月27日 內容資訊: 英文 49 Pages
簡介

RedHill Biopharma Ltd.是總公司設立於以色列的生物製藥企業。擁有處於後臨床階段並保有專利的消化器官疾病及發炎的開發中產品。

本報告提供RedHill Biopharma Ltd.的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

RedHill Biopharma Ltd.的基本資料

  • RedHill Biopharma Ltd.概要
  • 主要資訊
  • 企業資料

RedHill Biopharma Ltd.:R&D概要

  • 主要的治療範圍

RedHill Biopharma Ltd.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 聯合治療模式
  • 合作夥伴產品

RedHill Biopharma Ltd.:開發中產品概況

  • 後期階段產品開發中產品
    • 登記前階段的產品/聯合治療模式
    • 申請駁回的產品/聯合治療模式
    • 第Ⅲ相的產品/聯合治療模式
  • 臨床階段的開發中產品
    • 第Ⅱ相的產品/聯合治療模式
    • 第Ⅰ相的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

RedHill Biopharma Ltd.:藥物簡介

  • ondansetron hydrochloride CR
  • rizatriptan benzoate
  • (rifabutin + amoxicillin sodium + omeprazole sodium)
  • (rifabutin + clarithromycin + clofazimine)
  • carvedilol CR
  • upamostat
  • ABC-294640

RedHill Biopharma Ltd.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

RedHill Biopharma Ltd.:最近的開發平台資訊

RedHill Biopharma Ltd.:總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07124CDB

Summary

Global Markets Direct's, 'RedHill Biopharma Ltd. - Product Pipeline Review - 2015', provides an overview of the RedHill Biopharma Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of RedHill Biopharma Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of RedHill Biopharma Ltd. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of RedHill Biopharma Ltd.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the RedHill Biopharma Ltd.'s pipeline products

Reasons to buy

  • Evaluate RedHill Biopharma Ltd.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of RedHill Biopharma Ltd. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the RedHill Biopharma Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of RedHill Biopharma Ltd. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of RedHill Biopharma Ltd.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of RedHill Biopharma Ltd. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • RedHill Biopharma Ltd. Snapshot
    • RedHill Biopharma Ltd. Overview
    • Key Information
    • Key Facts
  • RedHill Biopharma Ltd. - Research and Development Overview
    • Key Therapeutic Areas
  • RedHill Biopharma Ltd. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • RedHill Biopharma Ltd. - Pipeline Products Glance
    • RedHill Biopharma Ltd. - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
      • Filing rejected/Withdrawn Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • RedHill Biopharma Ltd. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • RedHill Biopharma Ltd. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • RedHill Biopharma Ltd. - Drug Profiles
    • ondansetron hydrochloride CR
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • rizatriptan benzoate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (rifabutin + amoxicillin sodium + omeprazole sodium)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (rifabutin + clarithromycin + clofazimine)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • carvedilol CR
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • upamostat
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ABC-294640
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • RedHill Biopharma Ltd. - Pipeline Analysis
    • RedHill Biopharma Ltd. - Pipeline Products by Target
    • RedHill Biopharma Ltd. - Pipeline Products by Route of Administration
    • RedHill Biopharma Ltd. - Pipeline Products by Molecule Type
    • RedHill Biopharma Ltd. - Pipeline Products by Mechanism of Action
  • RedHill Biopharma Ltd. - Recent Pipeline Updates
  • RedHill Biopharma Ltd. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • RedHill Biopharma Ltd., Key Information
  • RedHill Biopharma Ltd., Key Facts
  • RedHill Biopharma Ltd. - Pipeline by Indication, 2015
  • RedHill Biopharma Ltd. - Pipeline by Stage of Development, 2015
  • RedHill Biopharma Ltd. - Monotherapy Products in Pipeline, 2015
  • RedHill Biopharma Ltd. - Combination Treatment Modalities in Pipeline, 2015
  • RedHill Biopharma Ltd. - Partnered Products in Pipeline, 2015
  • RedHill Biopharma Ltd. - Partnered Products/ Combination Treatment Modalities, 2015
  • RedHill Biopharma Ltd. - Pre-Registration, 2015
  • RedHill Biopharma Ltd. - Filing rejected/Withdrawn, 2015
  • RedHill Biopharma Ltd. - Phase III, 2015
  • RedHill Biopharma Ltd. - Phase II, 2015
  • RedHill Biopharma Ltd. - Phase I, 2015
  • RedHill Biopharma Ltd. - Preclinical, 2015
  • RedHill Biopharma Ltd. - Pipeline by Target, 2015
  • RedHill Biopharma Ltd. - Pipeline by Route of Administration, 2015
  • RedHill Biopharma Ltd. - Pipeline by Molecule Type, 2015
  • RedHill Biopharma Ltd. - Pipeline Products by Mechanism of Action, 2015
  • RedHill Biopharma Ltd. - Recent Pipeline Updates, 2015

List of Figures

  • RedHill Biopharma Ltd. - Pipeline by Top 10 Indication, 2015
  • RedHill Biopharma Ltd. - Pipeline by Stage of Development, 2015
  • RedHill Biopharma Ltd. - Monotherapy Products in Pipeline, 2015
  • RedHill Biopharma Ltd. - Combination Treatment Modalities in Pipeline, 2015
  • RedHill Biopharma Ltd. - Partnered Products in Pipeline, 2015
  • RedHill Biopharma Ltd. - Pipeline by Top 10 Target, 2015
  • RedHill Biopharma Ltd. - Pipeline by Top 10 Route of Administration, 2015
  • RedHill Biopharma Ltd. - Pipeline by Top 10 Molecule Type, 2015
  • RedHill Biopharma Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top